{"log_id": 4027152146361542745, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.004707, "average": 0.9806, "min": 0.546848}, "location": {"width": 797, "top": 205, "height": 55, "left": 197}, "words": "为20mgk/天(以AUC计,约为MRHD的27倍)。大鼠试验中,高剂量(以AUC计约"}, {"probability": {"variance": 8e-05, "average": 0.996845, "min": 0.946247}, "location": {"width": 803, "top": 255, "height": 51, "left": 198}, "words": "为MRHD的45倍)时可见良性腺性嗜铬细胞瘤、垂体腺瘤、胰腺腺瘤、肝细胞腺瘤(中及"}, {"probability": {"variance": 0.00168, "average": 0.987146, "min": 0.743705}, "location": {"width": 799, "top": 301, "height": 52, "left": 197}, "words": "高剂量)以及甲状腺滤泡瘤发生率增加;无影响剂量为5mg/kg天(以AUC计约为MRHD"}, {"probability": {"variance": 6e-06, "average": 0.997419, "min": 0.994048}, "location": {"width": 77, "top": 373, "height": 25, "left": 199}, "words": "的7倍)"}, {"probability": {"variance": 0.001312, "average": 0.987402, "min": 0.825246}, "location": {"width": 803, "top": 396, "height": 49, "left": 199}, "words": "机制性研究显示,普芦卡必利高浓度下D2受体拮抗作用可引起高催乳素血症,这可能是造"}, {"probability": {"variance": 1.2e-05, "average": 0.998269, "min": 0.978205}, "location": {"width": 805, "top": 442, "height": 48, "left": 201}, "words": "成小鼠和大鼠中的乳腺、垂体、胰腺和肾上腺肿瘤发生率增加的原因。高剂量下普芦卡必利"}, {"probability": {"variance": 1.6e-05, "average": 0.99777, "min": 0.980811}, "location": {"width": 804, "top": 487, "height": 51, "left": 202}, "words": "及其大鼠特异性代谢具有肝酶诱导作用,可能是造成大鼠肝脏和甲状腺肿瘤发生率增加的原"}, {"probability": {"variance": 2.3e-05, "average": 0.997205, "min": 0.977455}, "location": {"width": 804, "top": 535, "height": 49, "left": 202}, "words": "因。由于临床研究中没有观察到血浆催乳素水平增加,且普芦卡必利在人体中的代谢与大鼠"}, {"probability": {"variance": 4.7e-05, "average": 0.997438, "min": 0.966656}, "location": {"width": 492, "top": 590, "height": 41, "left": 203}, "words": "差异极大,因此这些肿瘤的发现被认为临床相关性较低"}, {"probability": {"variance": 7.2e-05, "average": 0.995017, "min": 0.974591}, "location": {"width": 130, "top": 647, "height": 27, "left": 210}, "words": "【药代动力学】"}, {"probability": {"variance": 0, "average": 0.999335, "min": 0.998843}, "location": {"width": 45, "top": 694, "height": 26, "left": 246}, "words": "吸收"}, {"probability": {"variance": 5.2e-05, "average": 0.995772, "min": 0.962255}, "location": {"width": 762, "top": 718, "height": 50, "left": 247}, "words": "2mg的普芦卡必利在单次口服给药后被迅速吸收,在2~3小时内达到血药浓度峰值"}, {"probability": {"variance": 0.00021, "average": 0.989239, "min": 0.942771}, "location": {"width": 709, "top": 765, "height": 50, "left": 208}, "words": "(mx)绝对口服生物利用度>90%。同时摄入食物不影响本品的口服生物利用度"}, {"probability": {"variance": 0, "average": 0.999901, "min": 0.999899}, "location": {"width": 43, "top": 832, "height": 25, "left": 249}, "words": "分布"}, {"probability": {"variance": 0.002946, "average": 0.985092, "min": 0.658216}, "location": {"width": 734, "top": 859, "height": 46, "left": 246}, "words": "本品分布广泛,稳态分布容积(Vds)为567升。本品的血浆蛋白结合率约为30%"}, {"probability": {"variance": 0, "average": 0.999893, "min": 0.999869}, "location": {"width": 43, "top": 922, "height": 27, "left": 253}, "words": "代谢"}, {"probability": {"variance": 5.3e-05, "average": 0.996286, "min": 0.958791}, "location": {"width": 759, "top": 948, "height": 47, "left": 253}, "words": "代谢不是本品清除的主要途径。在体外,通过人类肝脏代谢非常缓慢,仅有少量代谢产"}, {"probability": {"variance": 9e-06, "average": 0.998201, "min": 0.984405}, "location": {"width": 805, "top": 994, "height": 49, "left": 211}, "words": "物。在一项放射标记的人体口服给药研究中,在尿及粪便中回收了少量的八种代谢产物。主"}, {"probability": {"variance": 0.004365, "average": 0.983401, "min": 0.565507}, "location": {"width": 786, "top": 1042, "height": 47, "left": 213}, "words": "要代谢产物(R107504,通过O-甲基化和氧化形成,将羟基氧化成羧酸)占给药量不到4%"}, {"probability": {"variance": 9e-06, "average": 0.997584, "min": 0.989507}, "location": {"width": 801, "top": 1085, "height": 50, "left": 213}, "words": "原型药物占了血浆中总放射性物质的大约85%,只有R107504是血浆中的一种微量代谢产"}, {"probability": {"variance": 0, "average": 0.999983, "min": 0.999983}, "location": {"width": 25, "top": 1154, "height": 24, "left": 214}, "words": "物"}, {"probability": {"variance": 0.017904, "average": 0.866128, "min": 0.732321}, "location": {"width": 44, "top": 1199, "height": 25, "left": 256}, "words": "排泄"}, {"probability": {"variance": 0.000218, "average": 0.99523, "min": 0.907554}, "location": {"width": 765, "top": 1223, "height": 49, "left": 255}, "words": "大部分药物以原型排泄(在尿中大约为给药量的60%,在粪便中至少为6%)。原型药"}, {"probability": {"variance": 0.001237, "average": 0.984994, "min": 0.846198}, "location": {"width": 804, "top": 1269, "height": 49, "left": 217}, "words": "物的肾脏排泄涉及被动过滤及主动分泌。本品的血浆清除率平均为317m/min。其终末半衰"}, {"probability": {"variance": 3e-05, "average": 0.996904, "min": 0.972921}, "location": {"width": 801, "top": 1315, "height": 49, "left": 219}, "words": "期约为一天。在三到四天内达到稳态。每日一次以2mg本品进行治疗时,稳态血浆浓度的"}, {"probability": {"variance": 0.002815, "average": 0.980551, "min": 0.714391}, "location": {"width": 660, "top": 1365, "height": 46, "left": 218}, "words": "谷值和峰值分别为2.5ng/ml和7ng/ml。每日一次给药后的累积比在19到"}, {"probability": {"variance": 0.001859, "average": 0.982185, "min": 0.771918}, "location": {"width": 693, "top": 1405, "height": 57, "left": 221}, "words": "必利的药代动力学在治疗剂量至超剂量(达20mg)范围内均呈剂量相关在"}, {"probability": {"variance": 0, "average": 0.833242, "min": 0.833242}, "location": {"width": 44, "top": 1394, "height": 48, "left": 1045}, "words": "为"}, {"probability": {"variance": 1.3e-05, "average": 0.997612, "min": 0.988375}, "location": {"width": 412, "top": 1464, "height": 38, "left": 222}, "words": "每日一次使用本品显示出非时间依赖性动力学"}, {"probability": {"variance": 1e-06, "average": 0.999153, "min": 0.997512}, "location": {"width": 83, "top": 1517, "height": 28, "left": 265}, "words": "特殊人群"}, {"probability": {"variance": 2e-06, "average": 0.998354, "min": 0.994945}, "location": {"width": 147, "top": 1559, "height": 29, "left": 265}, "words": "群体药代动力学"}, {"probability": {"variance": 0.000948, "average": 0.978388, "min": 0.925074}, "location": {"width": 112, "top": 1643, "height": 42, "left": 1083}, "words": "仅供存档"}], "language": 3}